Precision Phenotypes News Today

Neumora Expands Precision Neuroscience Pipeline with Novel M4 Receptor Modulator Program Through Exclusive License Agreement with Vanderbilt University - read this article along with other careers information, tips and advice on BioSpace

Neumora Therapeutics has formally launched with $500 million and the goal of bringing to market precision therapies targeting neuropsychiatric disorders and neurodegenerative diseases stemming from disorders of the brain.

/PRNewswire/ -- Amgen (NASDAQ: AMGN) and Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company pioneering precision medicines for...

Press release content from PR Newswire. The AP news staff was not involved in its creation.